Literature DB >> 24906975

Relationship between glucose metabolism and non-alcoholic fatty liver disease severity in morbidly obese women.

Giorgio Bedogni1,2, Amalia Gastaldelli3, Claudio Tiribelli4, Fiorenza Agosti5, Alessandra De Col5, Rezene Fessehatsion6, Alessandro Sartorio5,6.   

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is an independent predictor of type 2 diabetes mellitus (T2DM). Insulin resistance and beta-cell dysfunction are involved in the pathogenesis of T2DM. Insulin resistance is associated with NAFLD but little is known about beta-cell dysfunction and NAFLD. AIM: We tested whether NAFLD severity is associated with insulin sensitivity and beta-cell function in morbidly obese women. SUBJECTS AND METHODS: We studied 61 Caucasian women aged 18-60 years without T2DM and with a body mass index ranging from 35.3 to 48.8 kg/m². The insulin sensitivity index (ISI) and the disposition index (DI) from oral glucose tolerance testing were used as measures of insulin sensitivity and beta-cell function, respectively. Fat was measured by dual-energy X-ray absorptiometry. Fatty liver was diagnosed by ultrasonography and ordinally coded as 0 = none, 1 = light, 2 = moderate, 3 = severe. Proportional-odds logistic regression was used to evaluate the association of NAFLD severity with log(e)ISI and log(e)DI with and without correction for total and truncal fat.
RESULTS: The odds of more severe vs. less severe NAFLD decreased for increasing log(e)ISI [odds ratio (OR) 0.40, 95 % CI 0.19-0.84, p < 0.05] and log(e)DI (OR 0.80, 95 % CI 0.69-0.92, p < 0.01). Neither total nor truncal fat had any effect on these associations.
CONCLUSION: In morbidly obese women, NAFLD severity is inversely associated with insulin sensitivity and beta-cell function. The association of NAFLD severity with beta-cell dysfunction is stronger than that with insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24906975     DOI: 10.1007/s40618-014-0101-x

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  22 in total

1.  A position statement on NAFLD/NASH based on the EASL 2009 special conference.

Authors:  Vlad Ratziu; Stefano Bellentani; Helena Cortez-Pinto; Chris Day; Giulio Marchesini
Journal:  J Hepatol       Date:  2010-05-07       Impact factor: 25.083

2.  Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity.

Authors:  Giovanni Musso; Roberto Gambino; Maurizio Cassader; Gianfranco Pagano
Journal:  Ann Med       Date:  2010-11-02       Impact factor: 4.709

3.  Obesity: preventing and managing the global epidemic. Report of a WHO consultation.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  2000

4.  Relationship between fatty liver and glucose metabolism: a cross-sectional study in 571 obese children.

Authors:  G Bedogni; A Gastaldelli; M Manco; A De Col; F Agosti; C Tiribelli; A Sartorio
Journal:  Nutr Metab Cardiovasc Dis       Date:  2010-09-28       Impact factor: 4.222

5.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

Authors:  M Matsuda; R A DeFronzo
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

6.  A simple index of lipid overaccumulation is a good marker of liver steatosis.

Authors:  Giorgio Bedogni; Henry S Kahn; Stefano Bellentani; Claudio Tiribelli
Journal:  BMC Gastroenterol       Date:  2010-08-25       Impact factor: 3.067

7.  Body fat distribution and insulin resistance: beyond obesity in nonalcoholic fatty liver disease among overweight men.

Authors:  Seung Ha Park; Byung Ik Kim; Sang Hoon Kim; Hong Joo Kim; Dong Il Park; Yong Kyun Cho; In Kyung Sung; Chong Il Sohn; Hyang Kim; Dong Keuk Keum; Heung Dae Kim; Jung Ho Park; Jin Ho Kang; Woo Kyu Jeon
Journal:  J Am Coll Nutr       Date:  2007-08       Impact factor: 3.169

8.  Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus.

Authors:  Ralph A Defronzo
Journal:  Diabetes       Date:  2009-04       Impact factor: 9.461

9.  The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population.

Authors:  Giorgio Bedogni; Stefano Bellentani; Lucia Miglioli; Flora Masutti; Marilena Passalacqua; Anna Castiglione; Claudio Tiribelli
Journal:  BMC Gastroenterol       Date:  2006-11-02       Impact factor: 3.067

10.  Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates.

Authors:  Ralph A Defronzo; Devjit Tripathy; Dawn C Schwenke; Maryann Banerji; George A Bray; Thomas A Buchanan; Stephen C Clement; Amalia Gastaldelli; Robert R Henry; Abbas E Kitabchi; Sunder Mudaliar; Robert E Ratner; Frankie B Stentz; Nicolas Musi; Peter D Reaven
Journal:  Diabetes       Date:  2013-07-17       Impact factor: 9.461

View more
  8 in total

Review 1.  NAFLD/NASH in patients with type 2 diabetes and related treatment options.

Authors:  M G Radaelli; F Martucci; S Perra; S Accornero; G Castoldi; G Lattuada; G Manzoni; G Perseghin
Journal:  J Endocrinol Invest       Date:  2017-11-30       Impact factor: 4.256

2.  Does segmental body composition differ in women with Prader-Willi syndrome compared to women with essential obesity?

Authors:  G Bedogni; G Grugni; G Tringali; N Marazzi; A Sartorio
Journal:  J Endocrinol Invest       Date:  2015-04-04       Impact factor: 4.256

Review 3.  Hepatic Steatosis as a Marker of Metabolic Dysfunction.

Authors:  Elisa Fabbrini; Faidon Magkos
Journal:  Nutrients       Date:  2015-06-19       Impact factor: 5.717

4.  Hepatic estrogen receptor α is critical for regulation of gluconeogenesis and lipid metabolism in males.

Authors:  Shuiqing Qiu; Juliana Torrens Vazquez; Erin Boulger; Haiyun Liu; Ping Xue; Mehboob Ali Hussain; Andrew Wolfe
Journal:  Sci Rep       Date:  2017-05-10       Impact factor: 4.379

Review 5.  Metabolic control of gene transcription in non-alcoholic fatty liver disease: the role of the epigenome.

Authors:  Matthew C Sinton; David C Hay; Amanda J Drake
Journal:  Clin Epigenetics       Date:  2019-07-18       Impact factor: 6.551

Review 6.  The Liver in Children With Metabolic Syndrome.

Authors:  Ebe D'Adamo; Valeria Castorani; Valerio Nobili
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-02       Impact factor: 5.555

7.  Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers.

Authors:  Kwangsik Nho; Alexandra Kueider-Paisley; Shahzad Ahmad; Siamak MahmoudianDehkordi; Matthias Arnold; Shannon L Risacher; Gregory Louie; Colette Blach; Rebecca Baillie; Xianlin Han; Gabi Kastenmüller; John Q Trojanowski; Leslie M Shaw; Michael W Weiner; P Murali Doraiswamy; Cornelia van Duijn; Andrew J Saykin; Rima Kaddurah-Daouk
Journal:  JAMA Netw Open       Date:  2019-07-03

8.  Twenty-five-year trajectories of insulin resistance and pancreatic β-cell response and diabetes risk in nonalcoholic fatty liver disease.

Authors:  Lisa B VanWagner; Hongyan Ning; Norrina B Allen; Juned Siddique; April P Carson; Michael P Bancks; Cora E Lewis; John Jeffrey Carr; Elizabeth Speliotes; Norah A Terrault; Mary E Rinella; Miriam B Vos; Donald M Lloyd-Jones
Journal:  Liver Int       Date:  2018-04-24       Impact factor: 8.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.